A novel estimator of between-study variance in random-effects models

Nan Wang1†, Jun Zhang2†, Li Xu3†, Jing Qi1, Beibei Liu1, Yiyang Tang4, Yinan Jiang5, Liang Cheng6, Qinghua Jiang7, Xunbo Yin1 and Shuilin Jin1*

Abstract

Background: With the rapid development of high-throughput sequencing technologies, many datasets on the same biological subject are generated. A meta-analysis is an approach that combines results from different studies on the same topic. The random-effects model in a meta-analysis enables the modeling of differences between studies by incorporating the between-study variance.

Results: This paper proposes a moment estimator of the between-study variance that represents the across-study variation. A new random-effects method (DSLD2), which involves two-step estimation starting with the DSL estimate and the $D_2$ in the second step, is presented. The DSLD2 method is compared with 6 other meta-analysis methods based on effect sizes across 8 aspects under three hypothesis settings. The results show that DSLD2 is a suitable method for identifying differentially expressed genes under the first hypothesis. The DSLD2 method is also applied to Alzheimer’s microarray datasets. The differentially expressed genes detected by the DSLD2 method are significantly enriched in neurological diseases.

Conclusions: The results from both simulationes and an application show that DSLD2 is a suitable method for detecting differentially expressed genes under the first hypothesis.

Keywords: Differentially expressed genes, Between-study variance, Random-effects model, Meta-analysis

Background

With the advances of high-throughput experimental technology, a multitude of datasets have been produced and have resulted in several public databases, such as the European Bioinformatics Institute (EBI) and Gene Expression Omnibus database (GEO) [1]. A major challenge is how to re-exploit, re-extract and combine the information from a large number of datasets [2]. A meta-analysis, combining data or results from independent studies on the same topic, is widely applied and the major contribution is discovering disease pathogenesis [3, 4]. The statistical power could be raised through meta-analysis by combining information from individual studies that have small sample sizes [5, 6]. Although many significantly differential gene expression lists are presented, individual conclusions tend to be discordant because of various study designs, individual treatment protocols, limited sample sizes and different genders among the study participants [7]. Meta-analysis is an important method for providing reliable and consistent differentially expressed gene lists by integrating information on the same disease [8]. As meta-analysis methods use available datasets, they are relatively inexpensive [9]. But not all datasets are usually available due to publication bias and outcome reporting bias [10].

Meta-analysis methods based on effect sizes, which contribute to the early diagnosis and treatment of diseases, can be broadly divided into two classes: the fixed-effects model (FEM) and the random-effects model (REM) [11]. The fixed-effects model assumes that all studies in a meta-analysis have the same true effect size [12]. The random-effects model assumes that different studies in a meta-analysis have the different true effect sizes [12]. The random-effects model assumes that different studies in a meta-analysis have the different true effect sizes [12].

Meta-analyses were first introduced to microarray data by Rhode et al. (2002) [13] and Choi et al. (2003) [14]. Many
meta-analysis methods, including DerSimonian and Laird estimate (DSL) [15], restricted maximum likelihood estimate (RML) and Sidik and Jonkman estimate (SJ) [16], were later applied to microarray studies. Two-step estimate starting with the DSL estimate (DL2) is an iterative estimator. The two-step method DL2 and the iterative Paule and Mandel method are close [17]. The random-effects methods in meta-analysis make possible the modeling of differences and the differences between studies often caused by the study design, sample sizes, sex/gender differences in participants and so on. The between-study variance $\tau^2$ is incorporated by random-effects methods in meta-analyses to estimate the across-study variation [18]. The fixed-effects model in meta-analyses excludes the between-study variance $\tau^2$ from the random-effects model [19].

This paper develops an estimator of the between-study variance $D^2_g$ which originates from the general moments estimator described by DerSimonian and Kacker (2007). Therefore, a new random-effects method (DSLD2) based on $D^2_g$ is presented. In subsequent sections, three hypothesis testing frameworks were thoroughly reviewed. We observed the biases and root mean square errors (RMSE) of between-study variance $D^2_g$. The random-effects method based on $D^2_g$ and other meta-analysis models were applied to simulation datasets of gene expression levels. Then, we compared the DSLD2 method with other meta-analysis methods, including the DSL method, the DSLR2 method, the fixed-effects model, the PM method, the RML method and the SJ method across the following metrics: the false discovery rates (FDRs), accuracy, precision, false positive rate (FPR), sensitivity, precision-recall curve and the receiver operating characteristic curve (ROC). DSLD2 performed well among the meta-analysis methods based on effect sizes under the first hypothesis. We also applied DSLD2 to Alzheimer’s disease. The pathways of differentially expressed genes detected by the DSLD2 method indicate that Alzheimer’s disease is related to the nervous system, which is obvious. The results from both the simulation and the application suggest that DSLD2 is appropriate for identifying differentially expressed genes. In addition, we prove the reasonableness of the between-study variance $D^2_g$ in Additional file 1.

Methods

Underlying hypothesis settings

Statistical hypothesis tests are primarily used in meta-analyses to identify differentially expressed genes, and three common hypothesis testing frameworks are often applied [20]. In the first hypothesis test, targeted biomarkers are differentially expressed genes with non-zero effect sizes in all studies. The null and alternative hypotheses are as follows:

$$H_0: \bigcap_{i=1}^{k} \{\theta_{ig} = 0\} \quad \text{vs} \quad H_A: \bigcup_{i=1}^{k} \{\theta_{ig} \neq 0\}$$

(The first hypothesis)

where $\theta_{ig}$ denotes the underlying true effect size for gene $g$ in study $i (i = 1, 2, \ldots, k)$, $k$ is the number of studies in a meta-analysis. The second hypothesis test aims to determine a differentially expressed gene with non-zero effect sizes in one or more studies. The null and alternative hypotheses are as follows:

$$H_0: \bigcap_{i=1}^{k} \{\theta_{ig} = 0\} \quad \text{vs} \quad H_A: \bigcup_{i=1}^{k} \{\theta_{ig} \neq 0\}$$

(The second hypothesis)

The third hypothesis test aims to determine a differential gene expression if it has non-zero effect sizes in the majority of studies (half or more). The null and alternative hypotheses are as follows:

$$H_0: \sum_{i=1}^{k} I(\theta_{ig} \neq 0) < r \quad \text{vs} \quad H_A: \sum_{i=1}^{k} I(\theta_{ig} \neq 0) \geq r$$

(The third hypothesis)

where the indicator function is denoted by $I(\cdot)$, which takes a value of 0 if $\theta_{ig} = 0$ and a value of 1 if $\theta_{ig} \neq 0$. $r$ is the number of studies that we identify a differentially expressed gene in at least $r$ studies. $r$ is usually set as greater than 0.5$k$. For instance, we can define a differentially expressed gene if it is significant in at least 4 ($r = 4$) of 8 studies.

Meta-analysis methods based on effect sizes

Fixed-effects model

The fixed-effects model (FEM) assumes that all studies included in the meta-analysis have the same true effect size and that the difference in the observed effect between combined studies is caused by random error [21]. The observed effect sizes of each study are combined with a simple linear model.

Random-effects model

Let $\mu_g$ be the overall mean for gene $g$, which is a typical parameter of interest. $y_{ig}$ denotes the observed effect size for gene $g$ in study $i (i = 1, 2, \ldots, k)$. The random-effects model is given by

$$y_{ig} = \mu_g + \xi_{ig} + \varepsilon_{ig}, \xi_{ig} \sim N\left(0, \sigma^2_{ig}\right), \varepsilon_{ig} \sim N\left(0, \sigma^2_{ig}\right)$$

where $\xi_{ig}$ is the random effect for gene $g$ in study $i$ and obeys a normal distribution with mean 0 and variance $\sigma^2_{ig}$, $\sigma^2_{ig}$ is the within-study variance representing the sampling error for gene $g$ in study $i$, and $\tau^2_g$ denotes the between-study variance which is the variability between studies. If $\tau^2_g = 0$, then the random-effects model reduces to a fixed-effects model. If $\hat{\sigma}^2_{ig}(i = 1, 2, \ldots, k)$ and $\hat{\tau}^2_g$ are the estimates of $\sigma^2_{ig}(i = 1, 2, \ldots, k)$ and $\tau^2_g$, the overall mean $\mu_g$ can be estimated by
\[ M_g = \frac{\sum_{i=1}^{k} \omega_g^* y_{ig}^2}{\sum_{i=1}^{k} \omega_g^*} = \left( \hat{\tau}_g^2 + \hat{\sigma}_g^2 \right)^{-1}. \]  

**DerSimonian and Laird estimate**

The between-study variance \( \tau_g^2 \) can be estimated by the DerSimonian–Laird (DSL) method

\[
\hat{\tau}_g^2 (DSL) = \max \left( 0, \frac{Q_g - (k - 1)}{\sum_{i=1}^{k} \omega_g y_{ig}^2} \right)
\]

where \( Q_g = \sum_{i=1}^{k} \omega_g (y_{ig} - M)^2, \omega_g = \hat{\sigma}_g^{-2}, M = \sum_{i=1}^{k} \omega_g y_{ig} / \sum_{i=1}^{k} \omega_g \) [22]. The estimator is not unbiased, but it is the simplest [23]. The DSL estimator is the most widely used method [24].

**Two-step estimation starting with the DSL estimate and the \( R^2_g \) in the second step (DSLR2)**

DSLR2 is a random-effects model based on the between-study variability \( R^2_g \) [17, 25], which yields

\[
R_g^2 = 1 - \frac{\sum_{i=1}^{k} \omega_g^* (y_{ig} - M_g)^2}{\sum_{i=1}^{k} \omega_g y_{ig}^2}
\]

where \( \omega_g^* = \left( \hat{\sigma}_g^2 + \hat{\tau}_g^2 (DSL) \right)^{-1} \), \( M_g = \sum_{i=1}^{k} \omega_g^* y_{ig} / \sum_{i=1}^{k} \omega_g^* \).

**Paule and Mandel estimate (PM)**

\( \hat{\tau}_g^2 (PM) \) is the unique solution of \( \sum_{i=1}^{k} \omega_g^* \left( y_{ig} - M_g^* \right)^2 \) \( \hat{\tau}_g^2 (PM) \) where \( \omega_g^* = \left( \hat{\sigma}_g^2 + \hat{\tau}_g^2 (PM) \right)^{-1} \) [26]. Negative \( \hat{\tau}_g^2 (PM) \) estimates truncate to 0. \( \hat{\tau}_g^2 (PM) \) is estimated and we can substitute it in \( \omega_g^* = \left( \hat{\sigma}_g^2 + \hat{\tau}_g^2 (PM) \right)^{-1} \) to obtain \( M_g^* \) \( \hat{\tau}_g^2 (PM) = \sum_{i=1}^{k} \omega_g^* y_{ig} / \sum_{i=1}^{k} \omega_g^* \) [26].

**Restricted maximum likelihood estimate**

The method of restricted maximum likelihood estimator (RML) can be used to calculate the estimators of overall mean value \( \mu_g \) and between-studies variance \( \tau_g^2 \) of a random-effects meta-analysis model [27]. The log-likelihood function based on the linear mixed effects model is

\[
l_g \left( \mu_g, \tau_g^2 \right) = -\frac{1}{2} \sum_{i=1}^{k} \ln \left( \sigma_g^2 + \tau_g^2 \right) \\
- \frac{1}{2} \sum_{i=1}^{k} \ln \left( \frac{\left( y_{ig} - \mu_g \right)^2}{\sigma_g^2 + \tau_g^2} \right) - \frac{1}{2} \ln \left( \sum_{i=1}^{k} \left( \sigma_g^2 + \tau_g^2 \right)^{-1} \right).
\]

The log-likelihood can be maximized using the Fisher scoring algorithm to obtain the estimates of \( \mu_g \) and \( \tau_g^2 \). Negative \( \tau_g^2 \) estimates are truncated to 0 [27].

**Sidik and Jonkman estimate**

The following two-step estimator of between-study variance \( \tau_g^2 \) was proposed by Sidik and Jonkman [28, 29]

\[
\hat{\tau}_g^2 (SJ) = \frac{1}{k - 1} \sum_{i=1}^{k} \frac{1}{1 + \hat{\sigma}_g^2 / \hat{\tau}_g^2} \left( y_{ig} - M_g^* (SJ) \right)^2
\]

where \( M_g^* (SJ) = \sum_{i=1}^{k} \omega_g y_{ig} / \sum_{i=1}^{k} \omega_g, \omega_g = \frac{1}{1 + \hat{\sigma}_g^2 / \hat{\tau}_g^2}, \hat{\tau}_g^2 = \max \{ 0.01, \frac{1}{k} \sum_{i=1}^{k} \left( y_{ig} - y_{Ag} \right)^2 - \frac{1}{k} \sum_{i=1}^{k} \hat{\tau}_g^2 \}, y_{Ag} = \frac{1}{k} \sum_{i=1}^{k} y_{ig} \).

**Two-step estimation starting with the DSL estimate and the \( D^2_g \) in the second step (DSLD2)**

The main component of the random-effects meta-analysis model is the between-study variability. We develop a between-study variability estimator \( D_g^2 \), which estimates the amount of conditional variance in \( y_{ig} \), which yields

\[
D_g^2 = \frac{Q_g - S_{MM_g}}{\sum_{i=1}^{k} \omega_g y_{ig}^2 - \sum_{i=1}^{k} \omega_g y_{ig}^2 / \sum_{i=1}^{k} \omega_g}
\]

where \( Q_g = \sum_{i=1}^{k} (y_{ig} - M_g)^2, S_{MM_g} = \sum_{i=1}^{k} (y_{ig} - M_g)^2 / \sum_{i=1}^{k} (\sigma_g^2 + \hat{\tau}_g^2) \).

Such an estimator of the between-study variance is always greater than 0 and indicates how strong the random effects are. The algorithm of the DSLD2 method is as follows:

- Calculate \( Q_g \) and \( \hat{\tau}_g^2 \) in Eq. (2).
- Calculate \( M_g^* \) in Eq. (1).
- Calculate \( D_g^2 \) in Eq. (3) and
- Replace \( \hat{\tau}_g^2 \) with \( D_g^2 \) in Eq. (1).

The weights, overall mean estimator, variance of the overall mean estimator, bounds of the confidence interval and z-statistics based on the between-study variance \( D_g^2 \) can be obtained by

\[
\omega_g \left( D_g^2 \right) = \frac{1}{\sigma_g^2 + D_g^2}, i = 1, 2, \ldots, k
\]

\[
M_g \left( D_g^2 \right) = \frac{\sum_{i=1}^{k} \omega_g (D_g^2) y_{ig}}{\sum_{i=1}^{k} \omega_g (D_g^2)}
\]

\[
Var \left( D_g^2 \right) = \frac{1}{\sum_{i=1}^{k} \omega_g (D_g^2)}
\]

\[
U.L \left( D_g^2 \right) = M_g \left( D_g^2 \right) + 1.96 \sqrt{Var \left( D_g^2 \right)}
\]

\[
L.L \left( D_g^2 \right) = M_g \left( D_g^2 \right) - 1.96 \sqrt{Var \left( D_g^2 \right)}
\]
Each sample in each study contained 40 gene clusters. Samples were controls, and the last 2000 genes and 2 were put into the third group (\(k_g = 3\)). The 801th gene to the 1000th gene were put into the fifth group (\(k_g = 5\)). The 1001th gene to the 2000th gene were put into the zeroth group (\(k_g = 0\)). The simulation algorithm is summarized as follows:

- We sampled \(\sum_{ck}^i \sim W^{-1}(\psi, 60)\) for genes in cluster \(c (1 \leq c \leq 40)\) and study \(k (1 \leq k \leq 5)\), where \(\psi = 0.5I_{20 \times 20} + 0.5I_{20 \times 20}\) was the identity matrix, \(I_{20 \times 20}\) was the matrix in which all elements equal 1, and \(W^{-1}\) denoted the inverse Wishart distribution. We then standardized \(\sum_{ck}^i\) into \(\sum_{ck}\) with all diagonal elements equaling 1.
- We sampled the expression levels of genes in clusters \(c\) and \(n\) as \(X_{\text{cluster}} = \left(X_{\text{cluster}}, \ldots, X_{\text{cluster}}\right)^T \sim \text{MVN}(0, \Sigma_{\text{cluster}})\), where \(1 \leq n \leq 2N\), \(1 \leq c \leq 40\) and \(1 \leq k \leq 5\). The gene expression levels are \(g \sim N(0, \sigma_g^2)\) for the gene in cluster 0, where \(\sigma_g^2 \sim U(0.8, 1.2)\). The gene expression levels remained unchanged, and the case samples were \(X_{\text{case}} = X_{\text{control}} + \epsilon_{\text{case}}\), where \(1 \leq g \leq 2000\), \(1 \leq n \leq N\), and \(1 \leq k \leq 5\).

Thus, the numbers for truly differentially expressed genes were 200, 1000 and 600 under the first hypothesis, the second hypothesis and the third hypothesis, respectively.

### Simulation setting using Monte Carlo method

Let \(X_{\text{cluster}}^i\) and \(X_{\text{case}}^i\) be the observations of \(g\)th iteration in the \(i\)th samples in the \(i\)th study from a control and a case group. Assume that \(X_{\text{cluster}}^i\) was sampled \(N(\mu_{\text{cluster}}^i, \sigma^2)\) and \(X_{\text{case}}^i\) was sampled \(N(\mu_{\text{case}}^i, \sigma^2)\). Let \(n_{\text{cluster}}^i\) and \(n_{\text{case}}^i\) be the sample sizes in the \(i\)th study. To simplify things, it was set that \(n_{\text{cluster}}^i = n_{\text{case}}^i = 20\). The following factors were set in the simulations: \(k = (5, 10, 20, 40, 80)\), \(\tau^2 = (0.0, 1.0)\), \(n = 40\) and \(g = 1, 2, \ldots, 1000\). The values of \(n_{\text{cluster}}^i\) were sampled from \(N(40, (40/3)^2)\). The standardized mean difference (SMD) and the mean difference (MD) were chosen as the effect size measures.

### Results

#### Simulation results

The numbers of differentially expressed genes with \(p < 0.05\) (DE1) or \(FDR < 0.05\) (DE2) identified by various meta-analysis models are presented in Table 1 [31]. More differentially expressed genes were identified by the fixed-effects model. The DSLD2 method detected fewer DE genes than the FEM and SJ methods. All methods had normal FDR1 levels and FDR2 levels except the FEM method. The FDR2 of FEM is 0.3808 and greater than other meta-
The FDR2 value of the DSLD2 method was 0.0236, which was smaller than that of the other 5 meta-analysis methods.

The number of DE genes and FDRs from each method in the simulation data are shown in Table 1.

| Method | Simulation: K = 5, N = 100, G = 2000 |
|--------|-----------------------------------|
|        | DE1 (p < 0.05) | DE2 (FDR < 0.05) | FDR1 | FDR2 |
| DSLD2  | 642          | 422            | 0.0165 | 0.0236 |
| DSLR2  | 609          | 425            | 0.0164 | 0.0352 |
| DSL    | 625          | 426            | 0.0258 | 0.0328 |
| PM     | 621          | 422            | 0.0260 | 0.0331 |
| FEM    | 1033         | 969            | 0.0361 | 0.3808 |
| RML    | 620          | 423            | 0.0260 | 0.0330 |
| SJ     | 696          | 483            | 0.0434 | 0.0641 |

Note: $K$ represents the number of studies on the same or related topic; $N$ denotes the number of the samples in every study; $G$ represents the number of genes in every sample; $DE_1$ represents the number of DE genes with $p < 0.05$; $DE_2$ represents the number of DE genes for which $FDR < 0.05$. $FDR_1$ and $FDR_2$ are obtained from Additional file 2. DSLD2 represents the random-effects methods based on $D_2$ proposed in this paper; DSLR2 represents the random-effects method based on $R^2$; DSL denotes the standard random-effects model; FEM is the fixed-effects model.

Histograms were constructed to compare the differences in differentially expressed genes ($p < 0.05$) among different groups detected by various meta-analysis methods (see Fig. 1). The numbers of studies that were differentially expressed for gene $g$ in 1 ~ 200, 201 ~ 400, 401 ~ 600, 601 ~ 800, 801 ~ 1000, 1001 ~ 2000 were 1, 2, 3, 4, 5 and 0, respectively. The DSLD2 method identified fewer DE genes in group 1, group 2 and group 0 (see Fig. 1). More differentially expressed genes were detected by the DSLD2 method in groups 3, 4 and 5 (see Fig. 1). The DE genes discovered by the DSLD2 method showed an increasing trend, and the differentially expressed genes in group 5 could be completely identified by the DSLD2 method (see Fig. 1). The numbers of DE genes identified by the DSLD2 method in every group were consistent with the data simulation method (see Fig. 1).

Precision is an important descriptor of random errors. Line graphs and tables were constructed to compare the precision among 7 meta-analysis methods (see Fig. 2, Additional file 3: Figures S1–S2 and Additional file 4: Tables S1–S3). The precision of all the methods increased significantly from 10 to 60 samples and fluctuated slightly between 60 and 220 samples under the first hypothesis, the second hypothesis and the third hypothesis (see Fig. 2, Additional file 3: Figures S1–S2). The precision of the DSLD2 method was lower than other methods in 10 studies, however, the precision values of DSLD2 method went up to 1.0 when numbers of sample sizes per study were larger than 60 under the first hypothesis. Under the first hypothesis, the DSLD2 method had the lowest precision among the meta-analysis methods combining effect sizes. Under the second and third hypothesis, the FEM method had the highest precision values among 7 meta-analysis methods combining effect sizes (see Additional file 3: Figures S1, S2 and Additional file 4: Tables S2, S3).

Accuracy is a critical descriptor of systematic errors. Among the meta-analysis methods based on effect sizes, DSLD2 had the highest accuracy among 7 meta-analysis methods based on effect sizes under the first hypothesis (see Fig. 3 and Additional file 4: Table S4). Under the first hypothesis, the accuracy of the DSLD2 method experienced a decrease from 10 to 100 samples and tended to be steady between 100 and 220 samples (Fig. 3). The accuracy of FEM method is the lowest among 7 meta-analysis methods based on effect sizes under the first hypothesis (see Fig. 3 and Additional file 4: Table S4). Under the second hypothesis, the accuracy of FEM method was highest among 7 meta-analysis methods (Additional file 3: Figure S3 and Additional file 4: Table S5). Under the third hypothesis, the SJ method had the highest accuracy values among 7 meta-analysis methods when the numbers of sample sizes per study were between 60 and 220 (Additional file 3: Figure S4 and Additional file 4: Table S6).

The false positive rate (FPR) is the probability of falsely rejecting the null hypothesis of a test. Under the first hypothesis, DSLD2 had the highest FPR value when number of sample sizes per study was 10 (see Fig. 5 and Additional file 4: Table S7). However, the FPR value of DSLD2 method went down to 0.0 when numbers of sample sizes per study were larger than 60 under the first hypothesis (see Fig. 4 and Additional file 4: Table S7). Under the first hypothesis, the DSLR2 method had the highest FPR values when numbers of sample sizes per study were more than 60 (see Fig. 4 and Additional file 4: Table S7). Under the second and the third hypothesis, the FEM method had the lowest FPR values among 7 meta-analysis methods (see Additional file 3: Figures S5, S6 and Additional file 4: Tables S8, S9).

The Matthews correlation coefficient (MCC), a numerical measure of correlation, indicates a statistical relationship between the predicted and observed binary classifications. An MCC close to 1 denotes perfect prediction. Under the first hypothesis, the DSLD2 method had the highest MCC among the 7 meta-analysis methods based on effect sizes (see Fig. 5 and Additional file 4: Table S10). The FEM method had the lowest MCC values among the 7 meta-analysis methods under the first hypothesis (see Fig. 5 and Additional file 4: Table S10). Under the first hypothesis, the SJ method had the lowest MCC values among the 6 random-effects meta-analysis methods (see Fig. 5 and Additional file 4: Table S10). Under the second hypothesis, the SJ method had the highest MCC values among the 7 meta-analysis methods combining effect sizes (see Additional file 3: Figures S1, S2 and Additional file 4: Tables S2, S3).
Fig. 1 The histograms of DE genes detected by the 7 meta-analysis methods. The DSLD2 method is proposed in this paper. Genes 1 to 200 are differentially expressed in only one study; genes 201 to 400 are differentially expressed in two studies; genes 401 to 600 are differentially expressed in three studies; genes 601 to 800 are differentially expressed in four studies; genes 801 to 1000 are differentially expressed in all studies; and genes 1001 to 2000 are not differentially expressed in any studies.

Fig. 5 and Additional file 4: Table S10). Under the second, the FEM method had the highest MCC values among the 7 meta-analysis methods (see Additional file 3: Figure S7 and Additional file 4: Table S11). Under the third hypothesis, the SJ method had the highest MCC values among 7 meta-analysis methods based on effect sizes when the numbers of sample sizes per study were between 60 and 220 (see Additional file 3: Figure S8 and Additional file 4: Table S12).

Sensitivity is a statistical measure of the performance of binary classification tests. Under the first hypothesis, the DSLD2 method had the highest sensitivity values among the 7 meta-analysis methods based on effect sizes (see Fig. 6 and Additional file 4: Table S13). The FEM method had the lowest sensitivity values among the 7 meta-analysis methods under the first hypothesis (see Fig. 6 and Additional file 4: Table S13). Under the second hypothesis, the 7 meta-analysis methods had close sensitivity curves (see Additional file 3: Figure S9 and Additional file 4: Table S14). Under the third hypothesis, the random-effect meta-analysis methods had close sensitivity curves which are higher than the curve of the FEM method. (see Additional file 3: Figure S10 and Additional file 4: Table S15).
The receiver operating characteristic curve (ROC) is a tool for selecting possibly optimal models, and the area under the curve (AUC) measures how well two diagnostic results can be distinguished. $AUC \in (0.9, 1.0]$, $AUC \in (0.7, 0.9]$ and $AUC \in (0.5, 0.7]$ represent high, moderate and low accuracy, respectively. The DSLD2 method had AUC values of 0.996, 0.940 and 0.979 under the first, second, and third hypotheses, respectively. Under the first hypothesis, the DSLD2 method had the highest ROC curve among all 7 meta-analysis methods (see Fig. 7). Under the second hypothesis, the ROC curve of the DSLD2 method was the highest among 6 random-effects methods (see Additional file 3: Figure S11). Under the third hypothesis, the roc curve of the DSLD2 method was highest among the 7 meta-analysis methods based on effect sizes (see Additional file 3: Figure S12).

When the labels are highly imbalanced, ROC-AUC may give pretty good results and be misleading. Precision-recall plots could provide the researcher with a more accurate prediction because they evaluate the proportion of true positives among positive predictions [32]. Under the first hypothesis, the precision-recall curve of DSLD2 method was the highest among seven meta-analysis methods (see Fig. 8). The precision-recall curves of FEM and DSLR2 were lower than other curves under the first hypothesis (see Fig. 8). The DSL, PM, RML and SJ methods had almost the same precision-recall curve under the first hypothesis (see Fig. 8). Under the second hypothesis, the precision-recall curve of DSLD2 method was the highest among the curves of random-effects meta-analysis methods (see Additional file 3: Figure S13). The random-effects meta-analysis methods had close precision-recall curves which are lower than the curve of FEM under the third hypothesis (see Additional file 3: Figure S14).

Bias and root mean square error (RMSE) are outcomes directly related to the between-study variance estimator $D^2$. The DSLD2, DSL, PM and RML methods had close bias and RMSE curves when $\tau^2$ was set to 0.0 and 1.0 (see Figs. 9, 10, 11 and 12, Additional file 3: Figures S15–S18 and Additional file 4: Tables S16-S23). The bias and RMSE
curves of DSLD2, DSL, PM and RML methods were lower than that of SJ and DSLR2 methods when SMD was chosen as the effect size measure and $\tau^2$ was set to 0.0 (see Figs. 9 and 10). The DSLR2 method had the lowest bias and RMSE curves when MD was chosen as the effect size measure and $\tau^2$ was set to 0.0 (see Figs. 11 and 12). The bias and RMSE values of DSLD2, DSL, PM and RML methods were lower than that of the SJ method when MD was chosen as the effect size measure and $\tau^2$ was set to 0.0 (see Figs. 11 and 12). The DSLD2, DSL, PM and RML methods had the close bias and RMSE curves when the between study variance was set to 1.0 (Additional file 3: Figures S15–S18).

The DSLD2, DSL, PM and RML methods had close mean values of $I^2$ (see Figs. 13 and 14, Additional file 3: Figures S19–S20 and Additional file 4: Tables S24–S27). The $I^2$ curves of DSLD2, DSL, PM and RML methods were lower than that of DSLR2 and SJ methods when SMD was chosen as the effect size measure (see Fig. 13 and Additional file 3: Figure S19). The $I^2$ values of DSLD2, DSL, PM and RML methods were higher than that of DSLR2 method when MD was chosen as the effect size measure (see Fig. 14 and Additional file 3: Figure S20). The SJ method had the highest $I^2$ curves when MD was chosen as the effect size measure (see Fig. 14 and Additional file 3: Figure S20).

**Application in genomic data**

**Alzheimer’s gene expression datasets**

Alzheimer’s disease (AD), a neurodegenerative disease, is common in elderly individuals [33]. The incidence of AD has increased and is increasingly diagnosed in younger individuals. However, the etiology of AD is still unknown [34]. In this section, we used the DSLD2 method to analyze Alzheimer’s disease from a genetic perspective. Seven public AD gene expression datasets of the hippocampus from postmortem brain samples were used in this paper. The phenotypic and gene expression data are available through GEO accession numbers GSE36980 [35], GSE29378 [36], GSE84422 [37], GSE1297 [38], GSE5281
Fig. 6 Plot of sensitivity under the first hypothesis. The DSLD2 method is developed in this paper. The sensitivity value of DSLD2 is the highest among that of the 7 meta-analysis methods.

Fig. 7 ROC curves of various meta-analysis methods under the first hypothesis. The DSLD2 method is developed in this paper. The ROC curve of DSLD2 is the highest among that of the 7 meta-analysis methods. The sample size of every study is 100.

[39–41], GSE28146 and GSE48350 [42–48]. After within-study data preprocessing, filtering out genes with very low gene expression and excluding small variation genes, the meta-analysis of the DSLD2 method was conducted on 3257 target genes in 305 subjects (168 AD and 137 controls).

A Venn diagram was plotted to compare DE genes ($p < 0.01$) detected by the DSLD2, PM, SJ and RML methods. The DSLD2, PM, SJ and RML methods identified 364, 454, 611, 410 significantly DE genes ($p < 0.01$), respectively (Fig. 15). The four meta-analysis methods found 299 overlapping DE genes. The DE genes detected by the DSLD2
method were different from DE genes identified by the PM, SJ and RML methods.

To biologically annotate the differentially expressed genes identified by DSLD2, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed using over-representation analysis (ORA), and the first ten pathways are listed in Table 2. The differentially expressed genes with \( p < 0.001 \) were significantly enriched in the neurological disease pathways, including the MAPK signaling pathway (hsa04010), the ErbB signaling pathway (hsa04012), Helicobacter pylori infection-induced epithelial cell signaling (hsa05120) and the hippo signaling pathway (hsa04392). Many studies have shown that Alzheimer’s disease is closely related to the MAPK signaling pathway. For example, Eun Kyung and Eui-Ju reported that deviation from
the control of the MAPK signaling pathway influenced the progression of Alzheimer’s disease [49]. ErbB, a key NRG1 receptor, plays a significant role in the development and plasticity of Alzheimer’s disease. Woo et al. showed that the upregulation of ErbB4 immunoreactivity implicates the development of AD pathology [50].

The relationship between Helicobacter pylori infection (Hp-I) and Alzheimer’s disease was investigated by histological diagnosis [51]. Studies have shown that the pathophysiology of AD is influenced by Helicobacter pylori infection through many mechanisms [51]. Many studies have suggested that Alzheimer’s disease is related to the hippo signaling pathway [52].

Discussion and conclusion
This paper proposed a meta-analysis method (DSLD2) based on new between-study variance estimator \( D_s^2 \). The biases and RMSE of \( D_s^2 \) were lowest among 6 meta analysis methods when \( \tau^2 \) was set to 0 and SMD was chosen as the effect size measure (see Figs. 9 and 10). The DSLD2, DSL, PM and RML methods had close bias and RMSE values when \( \tau^2 \) was set to 0 or 1 and SMD or MD was chosen as the effect size measure (see Figs. 9, 10, 11 and 12 and Additional file 3: Figures S15–S18). The \( I^2 \) values of DSLD2, DSL, PM and RML methods were close when the \( \tau^2 \) is set to 0.0 and 1.0 (see Figs. 13 and 14 and Additional file 3: Figures S19–S20).

We applied 7 meta-analysis methods based on effect sizes to simulation datasets of gene expression levels and compared the performance between the DSLD2 method and the other meta-analysis models. The FDR\(_1\) values of DSLD2 were smaller than that of DSL, PM, FEM, RML and SJ methods (see Table 1). The DSLD2 method had the lowest FDR\(_2\) values among
the 7 meta-analysis methods based on effect sizes (see Table 1).

Under the first hypothesis, the precision, accuracy, sensitivity, FPR and MCC of the DSLD2 method varied greatly from 10 to 20 samples but tended to be stable between 60 and 220 samples (see Figs. 2, 3, 4, 5 and 6). The accuracy, MCC, sensitivity, ROC and precision-recall curve of the DSLD2 method were the highest among the 7 meta-analysis methods (see Figs. 3, 5, 6, 7 and 8). The precision of DSLD2 method went up to 1.0 when the number of sample sizes per study was larger than 60 (see Fig. 2). The FPR of DSLD2 method went down to 0.0 when the number of sample sizes per study was larger than 60 (see Fig. 4). The FEM method had the lowest curves of precision, accuracy, sensitivity, FPR and MCC (see Figs. 2, 3, 4, 5 and 6). The curves of precision, accuracy, sensitivity, FPR and MCC for the SJ method was lowest among random-effects meta-analysis methods (see Figs. 2, 3, 4, 5 and 6). The results of this simulation show that DSLD2 is a suitable method for detecting differentially expressed genes under the first hypothesis.

Under the second hypothesis, the DSLD2 and DSLR2 methods had the highest sensitivity values of approximately 1.0 (see Additional file 3: Figure S9). The ROC curve and precision-recall curve of DSLD2 method were the highest among 6 random-effects methods (see Additional file 3: Figures S11 and S13). The FEM method had the highest values of the precision, accuracy, FPR and MCC among 7 meta-analysis methods based on effect sizes (see Additional file 3: Figures S1, S3, S5 and S7).

Under the third hypothesis, the DSLD2 method had the high sensitivity values of approximately 1.0 (see
Additional file 3: Figure S10). The ROC curve and precision-recall curve of DSLD2 method were the highest among 6 random-effects methods (see Additional file 3: Figures S12 and S14). The SJ method had the highest values of accuracy and MCC when number of sample sizes per study was between 60 to 220 (see Additional file 3: Figures S4 and S8). The FEM method had the highest precision values and the lowest FPR values (see Additional file 3: Figures S2 and S6).

We also applied the DSLD2 method to microarray data of Alzheimer’s disease. The differentially expressed genes with $p < 0.01$ were significantly enriched in the neurological disease pathways, including the MAPK signaling pathway, the ErbB signaling pathway, Helicobacter pylori infection-induced epithelial cell signaling and the hippo signaling pathway. Moreover, many previous studies suggest that Alzheimer’s disease is related to pathways that DSLD2 discovered [49–52].
Table 2 Pathways of the differentially expressed genes discovered by the DSLD2 method

| PathwayID | Pathway name                                           | C   | O  | E   | R   | P-value | FDR   |
|-----------|--------------------------------------------------------|-----|----|-----|-----|---------|-------|
| hsa05212  | Pancreatic cancer                                      | 66  | 7  | 1.22 | 5.72 | 0.0002  | 0.060 |
| hsa04010  | MAPK signaling pathway                                 | 255 | 13 | 4.72 | 2.75 | 0.0008  | 0.062 |
| hsa05200  | Pathways in cancer                                     | 397 | 17 | 7.35 | 2.31 | 0.0009  | 0.062 |
| hsa04012  | ErbB signaling pathway                                 | 88  | 7  | 1.63 | 4.29 | 0.0011  | 0.062 |
| hsa05311  | Shigellosis                                            | 65  | 6  | 1.20 | 4.97 | 0.0012  | 0.062 |
| hsa04962  | Vasopressin-regulated water reabsorption               | 44  | 5  | 0.81 | 6.13 | 0.0012  | 0.062 |
| hsa05120  | Epithelial cell signaling in Helicobacter pylori infection | 68  | 6  | 1.26 | 4.76 | 0.0015  | 0.062 |
| hsa04392  | Hippo signaling pathway                                | 29  | 4  | 0.53 | 7.44 | 0.0018  | 0.062 |
| hsa01522  | Endocrine resistance                                   | 98  | 7  | 1.81 | 3.85 | 0.0021  | 0.066 |
| hsa04520  | Adherens junction                                      | 74  | 6  | 1.37 | 4.37 | 0.0023  | 0.066 |

Note: C represents the number of reference genes in the category, O represents the number of genes in the category and also in the gene set, E represents expected number in the category, and R represents the ratio of enrichment.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s12864-020-6500-9.

Additional file 1: Proofs. Additional file 1 proves that the between-study variance $D_2^2$ is greater than zero and $D_2^2 = (\tau^2)_g$ increases with $\tau^2$.

Additional file 2: Supplementary methods. Additional file 2 gives the calculation processes of the false discovery rate, the precision, the accuracy, the false positive rate, the sensitivity and the Matthews correlation coefficient.

Additional file 3: Supplementary figures. Figure S1 Plot of the precision under the second hypothesis. Figure S2 Plot of the precision under the third hypothesis. Figure S3 Plot of the accuracy under the second hypothesis. Figure S4 Plot of the accuracy under the third hypothesis. Figure S5 Plot of the FPR under the second hypothesis. Figure S6 Plot of the FPR under the third hypothesis. Figure S7 Plot of the MCC under the second hypothesis. Figure S8 Plot of the MCC under the third hypothesis. Figure S9 Plot of the sensitivity under the second hypothesis. Figure S10 Plot of the sensitivity under the third hypothesis. Figure S11 Plot of the ROC curve and the AUC value under the second hypothesis. Figure S12 Plot of the ROC under the third hypothesis. Figure S13 Precision-recall plot under the second hypothesis. Figure S14 Precision-recall plot under the third hypothesis. Figure S15 Bias plot of 6 meta-analysis methods when $\tau^2$ is set to 1.0 and SMID is chosen as the effect size measure. Figure S16 RMSE plot of 6 meta-analysis methods when $\tau^2$ is set to 1.0 and SMID is chosen as the effect size measure. Figure S17 Bias plot of 6 meta-analysis methods when $\tau^2$ is set to 1.0 and MD is chosen as the effect size measure. Figure S18 RMSE plot of 6 meta-analysis methods when $\tau^2$ is set to 1.0 and MD is chosen as the effect size measure. Figure S19 Mean of $I^2$ plot of 6 meta-analysis methods when $\tau^2$ is set to 1.0 and MD is chosen as the effect size measure. Figure S20 Mean of $I^2$ plot of 6 meta-analysis methods when $\tau^2$ is set to 1.0 and MD is chosen as the effect size measure.

Additional file 4: Tables. Additional file 4 is the tables of the precision, accuracy, FPR, MCC and sensitivity under three hypothesis and tables of bias, RMSE and mean of $I^2$.

Additional file 5: The $r$ code. Additional file 5 is the code of the simulation setting for gene expression levels, the code of the simulation data using Monte Carlo method and the R code of DSLD2 method.

Abbreviations

AD: Alzheimer’s disease; AUC: The area under the receiver operating characteristic curve; DSL: DerSimonian and Laird estimate; DSLD2: Two-step estimation starting with the DSL estimate and the $D_2^2$ in the second step, DSLR2: Two-step estimation starting with the DSL estimate and the $R^2$ in the second step; EBI: European Bioinformatics Institute; FDR: False discovery rate; FEM: Fixed-effects model; FPR: False positive rate; GEO: Gene Expression Omnibus database; $I^2$: Heterogeneity statistic; PM: Paule and Mandel estimate; REM: Random-effects model; RML: Restricted maximum likelihood estimate; RMSE: Root mean square error; ROC: Receiver operating characteristic curve; SJ: Sidik and Jonkman estimate.

Acknowledgements

Not applicable.

Authors’ contributions

SJ and LX provided guidance for the entire study. QJ, XY and JQ collected the data. NW, BL and YT carried out the data analysis. LC, JZ and YJ wrote the manuscript. All authors read and approved the final manuscript.

Funding

This work is supported by the National Natural Science Foundation of China (grant no. 11971130), the Natural Science Foundation of Heilongjiang Province, China (grant no. A2015001). This work was partially supported by the National High-Tech Research and Development Program of China (863 Program) (nos. 2015AA020101 and 2015AA020108).

Availability of data and materials

The simulation datasets has been made publicly available (https://github.com/andWisdom/A-novel-estimator-of-between-study-variance-in-random-effects-models). The code of simulation datasets is shared in the article’s supplementary information files. The AD datasets analysed during the current study are available under entry numbers GSE36980, GSE29378, GSE84422, GSE1297, GSE5281, GSE28146 and GSE48350 from the GEO database in NCBI (http://www.ncbi.nlm.gov/geo). The R code used in this manuscript is public available in Additional file 5.

Ethics approval and consent to participate

Because the data in this meta-analysis are from published articles and the data are publicly available, it was not necessary to obtain ethics approval and consent to participate.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 School of Mathematics, Harbin Institute of Technology, Harbin, Heilongjiang, China. 2 Rehabilitation department, Heilongjiang Province Land Reclamation Headquarters General Hospital, Harbin, Heilongjiang, China. 3 College of Computer Science and Technology, Harbin Engineering University, Harbin, Heilongjiang, China.
References

1. Sudmant PH, Alexis MS, Burge CB. Meta-analysis of RNA-seq expression data across species, tissues and studies. Genome Biol. 2015;16:287.

2. Bagos PG. Genetic model selection in genome-wide association studies: robust methods and the use of meta-analysis. Stat Appl Genet Mol. 2013;12:285–309.

3. Barendregt JJ, Doi SA, Lee YY. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67:974–378.

4. Panagiotou OA, Willer CJ, Hirschhorn JN. The power of meta-analysis in genomic meta-analysis. Ann Appl Stat. 2014;8:777.

5. Ma T, Huo Z, Kuo A, Zhu L, Lin CW, Liu S, Wang L, Liu F, Rahman T, Chang LC, Kim S, Liu J, Park Y, Song C, Oesterreich S, Sibille E, Tseng GC. Metaomics: analysis pipeline and browser-based software suite for transcriptomic meta-analysis. Bioinformatics. 2019;35:1597–9.

6. Tseng GC, Feingold DG. Comprehensive literature review and statistical considerations for microarray meta-analysis. Nucleic Acids Res. 2012;40:3785–9.

7. Bolanos RD, Calderon MC. Introduction to traditional meta-analysis. Rev Gastroenterol Peru. 2014;34:45–51.

8. Ma T, Zhao Z, Zhu L, Fang Z, Zheng X, Lin CW, Liu S, Wang L, Liu F, Rahman T, Chang LC, Kim S, Liu J, Park Y, Song C, Oesterreich S, Sibille E, Tseng GC. Metaomics: analysis pipeline and browser-based software suite for transcriptomic meta-analysis. Bioinformatics. 2019;35:1597–9.

9. Tseng GC, Feingold DG. Comprehensive literature review and statistical considerations for microarray meta-analysis. Nucleic Acids Res. 2012;40:3785–9.

10. Bolanos RD, Calderon MC. Introduction to traditional meta-analysis. Rev Gastroenterol Peru. 2014;34:45–51.

11. McKenzie JE, Beller EM, Forbes AB. Introduction to systematic reviews and meta-analysis. Resplooraphy. 2016;21:626–37.

12. Borenstein M, Hedges LV, Higgins J, Rothstein H. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97–111.

13. Rhodes DR, Barrette TR, Rubin MA. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002;62:4427–33.

14. Choi JK, Eskin E. Increasing the power of meta-analysis of genome-wide association studies to detect heterogeneous effects. Bioinformatics. 2017;33:379–88.

15. Bolanos RD, Calderon MC. Introduction to traditional meta-analysis. Rev Gastroenterol Peru. 2014;34:45–51.

16. Tseng GC, Feingold DG. Comprehensive literature review and statistical considerations for microarray meta-analysis. Nucleic Acids Res. 2012;40:3785–9.

17. Li N, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74:785–94.

18. McKenize JE, Beller EM, Forbes AB. Introduction to systematic reviews and meta-analysis. Resplooraphy. 2016;21:626–37.

19. Borenstein M, Hedges LV, Higgins J, Rothstein H. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1:97–111.

20. Song C, Tseng GC. Hypothesis setting and order statistic for robust genomic meta-analysis. Ann Appl Stat. 2014;8:777.

21. Evangelou E, Ioannidis JP. Meta-analysis methods for genome-wide association studies and beyond. Nat Rev Genet. 2013;14:379–89.

22. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105–14.

23. van Aert R, Jackson D. Multistep estimators of the between-study variance: The relationship with the paule-mandel estimator. Stat Med. 2018;37:2616–29.

24. Mavridis D, Salanti G. A practical introduction to multivariate meta-analysis. Stat Methods Med Res. 2013;22:133–58.

25. Demidenko E, Sargent J, Omega T. Random effects coefficient of determination for mixed and meta-analysis models. Commun Stat Theory Methods. 2012;41:953–69.

26. Langan D, Higgin J, Simmonds M. Comparative performance of heterogeneity variance estimators in meta-analysis: A review of simulation studies. Res Synth Methods. 2016;8:191–88.

27. Veroniki A, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, Kuss O, Higgins J, Langan D, Salanti G. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7:55–79.

28. Srdika K, Jonkman J. A comparison of heterogeneity variance estimators in combining results of studies. Stat Med. 2007;26:1964–81.

29. Srdika K, Jonkman J. Simple heterogeneity variance estimation for meta-analysis. J R Stat Soc Ser C Appl Stat. 2005;54:367–84.

30. Chang LC, Lin HM, Sibille E. Meta-analysis methods for combining multiple expression profiles: comparisons, statistical characterization and an application guideline. BMC Bioinformatics. 2013;14:368.

31. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat. 2001;29:1165–88.

32. Saito T, Rehmsemeier M. The precision-recall plot is more informative than the roc plot when evaluating binary classifiers on imbalanced datasets. PLOS ONE. 2015;10:0116146.

33. Swets JA. Measuring the accuracy of diagnostic systems. Science. 1988;240:1285–93.

34. Gusevare ES, Carrasquillo MM, Bellenguez C. Genome-wide association interaction analysis for Alzheimer’s disease. Neurobiol Aging. 2014;35:2436–43.

35. Hokama M, Oka S, Leon J. Altered expression of diabetes-related genes in Alzheimer’s disease brains: the hisayama study. Cereb Cortex. 2013;24:2476–88.

36. Miller JA, Woltjer RL, Goodenour JM. Genes and pathways underlying regional and cell type changes in Alzheimer’s disease. Genome Med. 2013;5:48.

37. Wang M, Roussos P, McKenzie A. Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer’s disease. Genome Med. 2016;8:104.

38. Blalock EM, Geddes JW, Chen KC. Incontinent alzheimer’s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci. 2004;101:2173–8.

39. Liang WS, Duncley T, Beach TG. Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics. 2007;28:311–22.

40. Liang WS, Reiman EM, Valla J. Alzheimer’s disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci. 2004;101:2173–8.

41. Blalock EM, Buechel HM. Popovic jmicroarrayanalyses of laser-captured hippocampus reveal distinct gray and white matter signatures associated with incontinent alzheimer’s disease. J Chem Neuroanat. 2011;42:118–36.

42. Blaluck J, Nordhues BA, Hill SE. Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest. 2013;123:4158–69.

43. Astarita G, Jung KM, Berchtold NC. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in alzheimer’s disease. PLoS ONE. 2010;5:12538.

44. Cribs DH, Berchtold NC, Perreau V. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J Neuroinflamm. 2012;9:179.

45. Blalock EM, Nordhues BA, Hill SE. Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest. 2013;123:4158–69.

46. Astarita G, Jung KM, Berchtold NC. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in alzheimer’s disease. PLoS ONE. 2010;5:12538.

47. Cribs DH, Berchtold NC, Perreau V. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J Neuroinflamm. 2012;9:179.
48. Berchtold NC, Coleman PD, Cribbs DH. Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer’s disease. Neurobiol Aging. 2013;34:1653–61.
49. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010;1802:396–405.
50. Woo RS, Lee JH, Yu HN. Expression of erbB4 in the neurons of Alzheimer’s disease brain and app/ps1 mice, a model of Alzheimer’s disease. Anat Cell Biol. 2011;44:116–27.
51. Kountouras J, Tisolaki M, Gavalas E. Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology. 2006;66:938–40.
52. Wang SP, Wang LH. Disease implication of hyper-hippo signalling. Open Biol. 2016;6:160119.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.